Literature DB >> 29147811

C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein.

Minu Singh1,2, Tapas Mukhopadhyay3.   

Abstract

Here, we have studied in p53 null H1299 lung carcinoma cells, the dominant-negative effect of human p53 (h-p53) on buffalo p53 (b-p53) induced nuclear transactivation-dependent function. Recently, we have isolated and cloned the full-length cDNA of buffalo p53. Buffalo and human p53 proteins exhibit a high degree of structural and functional similarities. In transiently transfected H1299 cell line b-p53 appeared to be more sensitive to Mdm2-mediated degradation as compared to h-p53, although its ability to transactivate p21 promoter was stronger than that of the human counterpart. This higher transactivation ability of b-p53 was lost in the presence of h-p53 suggesting, a dominant-negative effect of h-p53 on b-p53's transactivation of p21 promoter. Both human and buffalo p53 proteins could hetero-oligomerize but the b-p53 could tetramerize much faster than the h-p53. A chimeric cDNA construct of human p53 was made where the 1-260 bp N-terminus was replaced with buffalo p53 counterpart and expressed in H1299 cell line. The tetramerization ability of the chimeric p53 protein was comparable to that of h-p53. Properties of b-p53 like stronger p21 transactivation and super sensitivity to Mdm2 mediated degradation were lacking in the chimeric protein. Thus, it is suggested that faster ability of tetramerization as well as higher transactivation property of buffalo p53 is determined by the interplay of N- and C-terminal domains through macromolecular interactions.

Entities:  

Keywords:  CDKN1A; Mdm2; Tetramerization domain; Tumor suppressor; Water buffalo

Mesh:

Substances:

Year:  2017        PMID: 29147811     DOI: 10.1007/s11010-017-3214-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

1.  Local structural elements in the mostly unstructured transcriptional activation domain of human p53.

Authors:  H Lee; K H Mok; R Muhandiram; K H Park; J E Suk; D H Kim; J Chang; Y C Sung; K Y Choi; K H Han
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

Review 2.  The MDM2-p53 interaction.

Authors:  Ute M Moll; Oleksi Petrenko
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

Review 3.  Some p53-binding proteins that can function as arbiters of life and death.

Authors:  A W Braithwaite; G Del Sal; X Lu
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

Review 4.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

5.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

6.  Isolation, characterization and functional analysis of full length p53 cDNA from Bubalus bubalis.

Authors:  Minu Singh; Suruchi Aggarwal; Ashok K Mohanty; Tapas Mukhopadhyay
Journal:  Gene       Date:  2015-05-21       Impact factor: 3.688

Review 7.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

8.  Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53.

Authors:  P Chène
Journal:  J Mol Biol       Date:  1999-05-21       Impact factor: 5.469

9.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

Review 10.  Structural biology of the tumor suppressor p53.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.